Our data demonstrate desirable biodistribution and therapeutic efficacy in A431/CCKBR tumor-bearing nude mice without toxic effects and thus, provides preclinical evidence for the development of safe and efficacious CCKBR-targeted α particle therapy (TAT). Here, CCKBR is linked to neoplasm.